Sigrid Nikol
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sigrid Nikol has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
Jaroslav Pelisek
Department of Cardiology and Angiology, University Hospital, University of Münster, Germany
11 shared publicationsChoukri Mekkaoui
9 shared publicationsMasumi Shimizu
7 shared publicationsAlexandra Fuchs
Department of Pediatric Cardiology, Klinikum Großhadern, Ludwig Maximilian University, Munich, Germany
6 shared publicationsAdam Golda
5 shared publicationsPierre H. Rolland
Laboratoire Cardiovasculaire, Faculté de Médécine, Université de Marseille, France
5 shared publications
Latest Publications
- 16 February 2016
- Vol. 35 (2) , 217-31
UEMS training requirements for angiology and vascular medicine: european standards of postgraduate medical specialist training (ETR Document).
- 16 February 2016
- Vol. 35 (2) , 217-31
UEMS training requirements for angiology and vascular medicine: european standards of postgraduate medical specialist training (ETR Document).
- 1 September 2014
- Published by Wiley in The Journal of Gene Medicine
- Vol. 16 (9-10) , 309-316
Angiogenic gene therapy does not cause retinal pathology
Background The potential negative influence of angiogenic gene therapy on the development or progression of retinal pathologies such as diabetic retinopathy (DR) or age‐related macular degeneration (AMD) has led to the systematic exclusion of affected patients from trials. We investigated the role of nonviral fibroblast factor 1 (NV1FGF) in two phase II, multinational, double‐blind, randomized, placebo‐controlled, gene therapy trials (TALISMAN 201 and 211). Methods One hundred and fifty‐two subjects with critical limb ischemia or claudication were randomized to receive eight intramuscular injections of 2.5 ml of NV1FGF at 0.2 mg/ml or 0.4 mg/dl or placebo. One hundred and fifty‐two patients received a plasmid dose of NV1FGF of up to 32 mg or placebo. All patients underwent a systematic ophthalmologic examination at baseline and at 3, 6 or 12 months following gene therapy. Twenty‐six of these patients (Münster subgroup) received a retinal fluorescence angiography at baseline and at final examination. Results Among those 26 patients, four of nine patients with diabetes suffered from nonproliferative DR. Three patients showed non‐exsudative AMD. No change of retinal morphology or function was observed in Münster subgroup of both TALISMAN trials independent of the intramuscular NV1FGF dosage applied. Conclusions Angiogenic gene therapy using NV1FGF is safe even in diabetics. Copyright © 2014 John Wiley & Sons, Ltd.
- 1 September 2014
- Published by Wiley in The Journal of Gene Medicine
- Vol. 16 (9-10) , 309-316
Angiogenic gene therapy does not cause retinal pathology
Background The potential negative influence of angiogenic gene therapy on the development or progression of retinal pathologies such as diabetic retinopathy (DR) or age‐related macular degeneration (AMD) has led to the systematic exclusion of affected patients from trials. We investigated the role of nonviral fibroblast factor 1 (NV1FGF) in two phase II, multinational, double‐blind, randomized, placebo‐controlled, gene therapy trials (TALISMAN 201 and 211). Methods One hundred and fifty‐two subjects with critical limb ischemia or claudication were randomized to receive eight intramuscular injections of 2.5 ml of NV1FGF at 0.2 mg/ml or 0.4 mg/dl or placebo. One hundred and fifty‐two patients received a plasmid dose of NV1FGF of up to 32 mg or placebo. All patients underwent a systematic ophthalmologic examination at baseline and at 3, 6 or 12 months following gene therapy. Twenty‐six of these patients (Münster subgroup) received a retinal fluorescence angiography at baseline and at final examination. Results Among those 26 patients, four of nine patients with diabetes suffered from nonproliferative DR. Three patients showed non‐exsudative AMD. No change of retinal morphology or function was observed in Münster subgroup of both TALISMAN trials independent of the intramuscular NV1FGF dosage applied. Conclusions Angiogenic gene therapy using NV1FGF is safe even in diabetics. Copyright © 2014 John Wiley & Sons, Ltd.
- 1 October 2008
- Vol. 10 (5) , 479-92
Gene therapy of cardiovascular disease.
Coronary and peripheral artery diseases are highly prevalent and characterized by an unmet requirement for medical treatment in the more advanced stages. These shortcomings comprise the requirement for vessel regeneration using therapeutic angiogenesis as well as the prevention of post-angioplasty restenosis using local gene therapy. Both therapeutic angiogenesis and gene therapy to prevent post-angioplasty restenosis have undergone extensive research in the past 17 years and have led to a number of phase II clinical trials and a phase III approval trial. The development of therapeutic strategies based on gene therapy over the last 7 years is reviewed, including data from animal studies as well as phase II clinical trials.
- 1 October 2008
- Vol. 10 (5) , 479-92
Gene therapy of cardiovascular disease.
Coronary and peripheral artery diseases are highly prevalent and characterized by an unmet requirement for medical treatment in the more advanced stages. These shortcomings comprise the requirement for vessel regeneration using therapeutic angiogenesis as well as the prevention of post-angioplasty restenosis using local gene therapy. Both therapeutic angiogenesis and gene therapy to prevent post-angioplasty restenosis have undergone extensive research in the past 17 years and have led to a number of phase II clinical trials and a phase III approval trial. The development of therapeutic strategies based on gene therapy over the last 7 years is reviewed, including data from animal studies as well as phase II clinical trials.
- Top Cited PapersOpen Access
- 1 May 2008
- Published by Elsevier in Molecular Therapy
- Vol. 16 (5) , 972-978
Therapeutic Angiogenesis With Intramuscular NV1FGF Improves Amputation-free Survival in Patients With Critical Limb Ischemia
- 1 May 2008
- Published by Elsevier in Molecular Therapy
- Vol. 16 (5) , 972-978
Top Cited PapersOpen AccessTherapeutic Angiogenesis With Intramuscular NV1FGF Improves Amputation-free Survival in Patients With Critical Limb Ischemia
- 1 January 2008
- Published by Taylor & Francis in Endothelium
- Vol. 15 (1) , 93-100
Meta-Analysis Shows Similar Risk of Thrombosis After Drug-Eluting Stent, Bare-Metal Stent, or Angioplasty
Coronary stent thrombosis remains an important problem after the implantation of different stent types. This study investigates the risk of stent thrombosis associated with the use of drug-eluting stents (DESs), bare-metal stents (BMSs) compared to balloon angioplasty. A meta-analysis of 28 randomized trials involving 5612 versus 7639 versus 2994 patients with coronary heart disease treated with DES, BMS, or balloon angioplasty was therefore performed. Comparing the implantation of DES versus BMS, DES was not found to increase the hazard for thrombosis up to 15 months (odds ratio [OR] = 0.86, 95% confidence interval [CI] 0.58 to 1.3, p < .48). There was also no significant difference in the hazard for subacute thrombosis (SAT) or late stent thrombosis (LST) in the DES versus BMSs group (OR = 0.86, 95% CI 0.50 to 1.5, p < .6 and OR = 0.92, 95% CI 0.50 to 1.68, p < .78, respectively). Comparing incidences of stent thromboses in patients receiving balloon angioplasty or implantation of BMS, the rate of SAT in the balloon angioplasty group (1.7% SAT) versus BMS group (1.8% SAT) was also similar (OR = 0.93, 95% CI 0.61 to 1.4, p < .71). Finally, there was no significant difference in the occurrence of stent thrombosis for the different coatings of DESs. In conclusion, the use of DES was not observed to have a significant effect on stent thrombosis events, compared with the implantation of BMS or balloon angioplasty.
- 1 January 2008
- Published by Taylor & Francis in Endothelium
- Vol. 15 (1) , 93-100
Meta-Analysis Shows Similar Risk of Thrombosis After Drug-Eluting Stent, Bare-Metal Stent, or Angioplasty
Coronary stent thrombosis remains an important problem after the implantation of different stent types. This study investigates the risk of stent thrombosis associated with the use of drug-eluting stents (DESs), bare-metal stents (BMSs) compared to balloon angioplasty. A meta-analysis of 28 randomized trials involving 5612 versus 7639 versus 2994 patients with coronary heart disease treated with DES, BMS, or balloon angioplasty was therefore performed. Comparing the implantation of DES versus BMS, DES was not found to increase the hazard for thrombosis up to 15 months (odds ratio [OR] = 0.86, 95% confidence interval [CI] 0.58 to 1.3, p < .48). There was also no significant difference in the hazard for subacute thrombosis (SAT) or late stent thrombosis (LST) in the DES versus BMSs group (OR = 0.86, 95% CI 0.50 to 1.5, p < .6 and OR = 0.92, 95% CI 0.50 to 1.68, p < .78, respectively). Comparing incidences of stent thromboses in patients receiving balloon angioplasty or implantation of BMS, the rate of SAT in the balloon angioplasty group (1.7% SAT) versus BMS group (1.8% SAT) was also similar (OR = 0.93, 95% CI 0.61 to 1.4, p < .71). Finally, there was no significant difference in the occurrence of stent thrombosis for the different coatings of DESs. In conclusion, the use of DES was not observed to have a significant effect on stent thrombosis events, compared with the implantation of BMS or balloon angioplasty.
- 1 August 2007
- Published by Hogrefe Publishing Group in Vasa
- Vol. 36 (3) , 165-173
Therapeutic angiogenesis for peripheral artery disease: Gene therapy
Peripheral artery disease is a highly prevalent disease which is characterised by a high unmet medical need particularly in the more advanced stages of disease. Recent advances in the knowledge of the complex regulation of angiogenesis and arteriogenesis and ways to its induction offer hope for a novel strategy that is based on the generation of such new vessels. This strategy termed "therapeutic angiogenesis" is a concept based on the use of angiogenic factors or stem cells or their combination to promote neovascularisation for the treatment of ischaemic tissues. This article reviews both regulation of angiogenesis and the development of therapeutic strategies based on this knowledge using gene therapy. This includes knowledge from animal experiments as well as from phase I and phase II clinical trials. This information may be particularly important at a time when angiogenesis gene therapy enters the stage of phase III clinical testing hopefully leading to the first time approval of this completely new class of drug in the near future. Following articles of this series will review therapeutic angiogenesis approaches based on cytokine therapy and stem cell therapy.
- 1 August 2007
- Published by Hogrefe Publishing Group in Vasa
- Vol. 36 (3) , 165-173
Therapeutic angiogenesis for peripheral artery disease: Gene therapy
Peripheral artery disease is a highly prevalent disease which is characterised by a high unmet medical need particularly in the more advanced stages of disease. Recent advances in the knowledge of the complex regulation of angiogenesis and arteriogenesis and ways to its induction offer hope for a novel strategy that is based on the generation of such new vessels. This strategy termed "therapeutic angiogenesis" is a concept based on the use of angiogenic factors or stem cells or their combination to promote neovascularisation for the treatment of ischaemic tissues. This article reviews both regulation of angiogenesis and the development of therapeutic strategies based on this knowledge using gene therapy. This includes knowledge from animal experiments as well as from phase I and phase II clinical trials. This information may be particularly important at a time when angiogenesis gene therapy enters the stage of phase III clinical testing hopefully leading to the first time approval of this completely new class of drug in the near future. Following articles of this series will review therapeutic angiogenesis approaches based on cytokine therapy and stem cell therapy.
- 1 July 2007
- Published by Springer Nature in Clinical Research in Cardiology Supplements
- Vol. 2 (4) , IV30-IV37
Gen- und Stammzelltherapie der peripheren arteriellen Verschlusskrankheit
- 1 July 2007
- Published by Springer Nature in Clinical Research in Cardiology Supplements
- Vol. 2 (4) , IV30-IV37
Gen- und Stammzelltherapie der peripheren arteriellen Verschlusskrankheit
- 1 February 2007
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 73 (3) , 443-445
Viral or non-viral angiogenesis gene transfer—New answers to old questions
- 1 February 2007
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 73 (3) , 443-445
Viral or non-viral angiogenesis gene transfer—New answers to old questions
- 1 October 2006
- Published by International Society of Endovascular Specialists in Journal of Endovascular Therapy
- Vol. 13 (5) , 616-629
Paclitaxel Delivered to Adventitia Attenuates Neointima Formation Without Compromising Re-Endothelialization After Angioplasty in a Porcine Restenosis Model
Purpose: To investigate the effect of paclitaxel delivered into the adventitia of pig femoral arteries on neointima formation and hyperplasia as well as re-endothelialization. Methods: Paclitaxel or vehicle was delivered into the adventitia of pig femoral arteries using a needle injection catheter following balloon overstretch. Arteries were then serially examined by angiography, Evan's blue staining, morphometry, and immunohistochemistry for up to 12 weeks. Results: Local adventitial delivery of paclitaxel significantly attenuated neointima formation. The area of neointima (0.41±0.17 versus 2.75±0.81 mm2, pConclusion: Paclitaxel delivered into the adventitia of pig femoral arteries effectively attenuates neointima formation after angioplasty without compromising re-endothelialization. Adventitial drug delivery may therefore be an alternative to drug-eluting stents for the prevention of restenosis.
- 1 October 2006
- Published by International Society of Endovascular Specialists in Journal of Endovascular Therapy
- Vol. 13 (5) , 616-629
Paclitaxel Delivered to Adventitia Attenuates Neointima Formation Without Compromising Re-Endothelialization After Angioplasty in a Porcine Restenosis Model
Purpose: To investigate the effect of paclitaxel delivered into the adventitia of pig femoral arteries on neointima formation and hyperplasia as well as re-endothelialization. Methods: Paclitaxel or vehicle was delivered into the adventitia of pig femoral arteries using a needle injection catheter following balloon overstretch. Arteries were then serially examined by angiography, Evan's blue staining, morphometry, and immunohistochemistry for up to 12 weeks. Results: Local adventitial delivery of paclitaxel significantly attenuated neointima formation. The area of neointima (0.41±0.17 versus 2.75±0.81 mm2, pConclusion: Paclitaxel delivered into the adventitia of pig femoral arteries effectively attenuates neointima formation after angioplasty without compromising re-endothelialization. Adventitial drug delivery may therefore be an alternative to drug-eluting stents for the prevention of restenosis.
- 7 April 2006
- Published by Wiley in The Journal of Gene Medicine
- Vol. 8 (7) , 835-844
C‐type natriuretic peptide for reduction of restenosis: gene transfer is superior over single peptide administration
Background Restenosis is still a significant clinical problem limiting the long‐term therapeutic success following balloon dilation or stent implantation. New approaches are necessary inhibiting neointima formation and simultaneously promoting re‐endothelialization. Therefore, long‐term therapeutic effects of adventitial liposome‐mediated C‐type natriuretic protein (CNP) gene and CNP peptide applications in a porcine model for restenosis post‐angioplasty were investigated. Methods For in vitro applications, primary cultures of porcine vascular smooth muscle cells (VSMCs) and endothelial cells (ECs) were used. Gene transfer was performed with cationic lipid DOCSPER [1,3‐dioleoyloxy‐2‐(N5‐carbamoylspermine)propane]. In vivo treatment of pig femoral arteries was adventitial using a needle injection catheter following balloon angioplasty. Arteries were investigated by angiography, Evan's blue staining, histomorphometry, immunohistochemistry, PCR and RT‐PCR. Results Using CNP gene transfer in vitro, 29.4 ± 7.2% reduction of cell proliferation in VSMCs was observed. In ECs, the CNP gene did not compromise cellular growth. For the CNP peptide the optimal concentration was 1 mM with 50.7 ± 11.3% reduction of VSMC proliferation and 12.1 ± 5.3% enhancement of growth of ECs. Three weeks following application in vivo complete re‐endothelialization was observed in all treated groups. At 3 months significant reduction of neointima formation was observed using CNP gene vs. CNP peptide (85.9 ± 7.8% vs. 63.3 ± 27.6% reduction, P < 0.05) compared to control treatment. Conclusion Periadventitial liposome‐mediated CNP gene transfer in vivo resulted in a significant long‐term reduction of neointima formation without compromising endothelial repair and was superior over single CNP peptide administration. Advantages of CNP are its physiological origin and simultaneous inhibition of VSMC proliferation and promotion of EC growth. Copyright © 2006 John Wiley & Sons, Ltd.
- 7 April 2006
- Published by Wiley in The Journal of Gene Medicine
- Vol. 8 (7) , 835-844
C‐type natriuretic peptide for reduction of restenosis: gene transfer is superior over single peptide administration
Background Restenosis is still a significant clinical problem limiting the long‐term therapeutic success following balloon dilation or stent implantation. New approaches are necessary inhibiting neointima formation and simultaneously promoting re‐endothelialization. Therefore, long‐term therapeutic effects of adventitial liposome‐mediated C‐type natriuretic protein (CNP) gene and CNP peptide applications in a porcine model for restenosis post‐angioplasty were investigated. Methods For in vitro applications, primary cultures of porcine vascular smooth muscle cells (VSMCs) and endothelial cells (ECs) were used. Gene transfer was performed with cationic lipid DOCSPER [1,3‐dioleoyloxy‐2‐(N5‐carbamoylspermine)propane]. In vivo treatment of pig femoral arteries was adventitial using a needle injection catheter following balloon angioplasty. Arteries were investigated by angiography, Evan's blue staining, histomorphometry, immunohistochemistry, PCR and RT‐PCR. Results Using CNP gene transfer in vitro, 29.4 ± 7.2% reduction of cell proliferation in VSMCs was observed. In ECs, the CNP gene did not compromise cellular growth. For the CNP peptide the optimal concentration was 1 mM with 50.7 ± 11.3% reduction of VSMC proliferation and 12.1 ± 5.3% enhancement of growth of ECs. Three weeks following application in vivo complete re‐endothelialization was observed in all treated groups. At 3 months significant reduction of neointima formation was observed using CNP gene vs. CNP peptide (85.9 ± 7.8% vs. 63.3 ± 27.6% reduction, P < 0.05) compared to control treatment. Conclusion Periadventitial liposome‐mediated CNP gene transfer in vivo resulted in a significant long‐term reduction of neointima formation without compromising endothelial repair and was superior over single CNP peptide administration. Advantages of CNP are its physiological origin and simultaneous inhibition of VSMC proliferation and promotion of EC growth. Copyright © 2006 John Wiley & Sons, Ltd.